Entos Pharmaceuticals Secures $77.5 Million Investment to Establish Advanced Biomanufacturing Facility in Edmonton
New 103,000-Square-Foot Facility to Enhance Canada's Biomanufacturing Capacity and Develop Next-Generation Genetic Medicines

Paul Chaytor
Jul 22, 2025
Entos Pharmaceuticals will receive a combined $77.5 million investment from the Canadian and Alberta governments to build a leading-edge genetic medicines facility in Edmonton.
The Government of Canada is contributing $62 million through the Strategic Innovation Fund, while Alberta will provide $15.5 million, supporting a $198.5 million, 103,000-square-foot centre for genetic medicine research and production.
Entos focuses on its innovative Fusogenix PLV drug delivery platform, promising breakthroughs for cancer, rare diseases, infections, and neurodegenerative disorders.
The new Edmonton facility is set to generate 90 high-paying jobs and 69 student co-op placements, boosting the city’s and Canada's biotech sector.
Backed by the Biomanufacturing and Life Sciences Strategy, construction is slated to begin by late 2025, positioning Edmonton as a national hub for biotechnology and attracting international collaborations and investment.